ESR1 and breast carcinoma: Taking a precision medicine perspective, a recent study by Zheng et al. published in Science Translational Medicine demonstrated that a subset of ER+ breast cancers exhibit heightened sensitivity to CDK4/6i, owing to their pronounced reliance on CDK4/6 activity for survival in the context of endocrine therapy [21].